Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial... www.nature.com/bjc ARTICLE Clinical Study Apatorsen plus docetaxel versus docetaxel alone in platinum- resistant metastatic urothelial carcinoma (Borealis-2) 1 2 3 3 4 5 6 7 Jonathan E. Rosenberg , Noah M. Hahn , Meredith M. Regan , Lillian Werner , Ajjai Alva , Saby George , Joel Picus , Robert Alter , 8 9 10 11 12 13 14 Arjun Balar , Jean Hoffman-Censits , Petros Grivas , Richard Lauer , Elizabeth A. Guancial , Christopher Hoimes , Guru Sonpavde , 15 16 17 18 18 3 3 Constantine Albany , Mark N. Stein , Tim Breen , Cindy Jacobs , Kirsten Anderson , Joaquim Bellmunt , Aly-Khan A. Lalani , 19 3 Sumanta Pal and Toni K. Choueiri BACKGROUND: A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy. METHODS: Multicentre, phase II study with 1:1 randomisation to apatorsen (three loading doses at 600 mg intravenous followed by weekly doses) plus docetaxel (75 mg/m intravenous every 21 days) (A/D) or docetaxel alone. Overall survival (OS) was the primary end point with a P value <0.1 (one-sided) being positive. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Cancer Springer Journals
Loading next page...
 
/lp/springer_journal/apatorsen-plus-docetaxel-versus-docetaxel-alone-in-platinum-resistant-LkKsKddlUp
Publisher
Nature Publishing Group UK
Copyright
Copyright © 2018 by Cancer Research UK
Subject
Biomedicine; Biomedicine, general; Cancer Research; Epidemiology; Molecular Medicine; Oncology; Drug Resistance
ISSN
0007-0920
eISSN
1532-1827
D.O.I.
10.1038/s41416-018-0087-9
Publisher site
See Article on Publisher Site

Abstract

www.nature.com/bjc ARTICLE Clinical Study Apatorsen plus docetaxel versus docetaxel alone in platinum- resistant metastatic urothelial carcinoma (Borealis-2) 1 2 3 3 4 5 6 7 Jonathan E. Rosenberg , Noah M. Hahn , Meredith M. Regan , Lillian Werner , Ajjai Alva , Saby George , Joel Picus , Robert Alter , 8 9 10 11 12 13 14 Arjun Balar , Jean Hoffman-Censits , Petros Grivas , Richard Lauer , Elizabeth A. Guancial , Christopher Hoimes , Guru Sonpavde , 15 16 17 18 18 3 3 Constantine Albany , Mark N. Stein , Tim Breen , Cindy Jacobs , Kirsten Anderson , Joaquim Bellmunt , Aly-Khan A. Lalani , 19 3 Sumanta Pal and Toni K. Choueiri BACKGROUND: A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy. METHODS: Multicentre, phase II study with 1:1 randomisation to apatorsen (three loading doses at 600 mg intravenous followed by weekly doses) plus docetaxel (75 mg/m intravenous every 21 days) (A/D) or docetaxel alone. Overall survival (OS) was the primary end point with a P value <0.1 (one-sided) being positive.

Journal

British Journal of CancerSpringer Journals

Published: May 16, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off